Related references
Note: Only part of the references are listed.ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
S. Gettinger et al.
ANNALS OF ONCOLOGY (2014)
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
Qinhua Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Kilian V. M. Huber et al.
NATURE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ROS1-Rearranged Lung Cancer A Clinicopathologic and Molecular Study of 15 Surgical Cases
Akihiko Yoshida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Identification of ROS1 Rearrangement in Gastric Adenocarcinoma
Jeeyun Lee et al.
CANCER (2013)
Molecular Pathways: ROS1 Fusion Proteins in Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
Justin F. Gainor et al.
ONCOLOGIST (2013)
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
PLOS ONE (2013)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
Hiroyuki Yasuda et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Ting-Lei Gu et al.
PLOS ONE (2011)
Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
Ashley H. Birch et al.
PLOS ONE (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A Charest et al.
GENES CHROMOSOMES & CANCER (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)